ANTONINI, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.309
EU - Europa 2.613
AS - Asia 2.336
Continente sconosciuto - Info sul continente non disponibili 14
SA - Sud America 12
OC - Oceania 11
AF - Africa 9
Totale 32.304
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.278
SG - Singapore 1.242
IT - Italia 887
CN - Cina 761
SE - Svezia 430
FI - Finlandia 358
FR - Francia 346
VN - Vietnam 225
GB - Regno Unito 224
DE - Germania 147
IE - Irlanda 60
NL - Olanda 53
IN - India 41
UA - Ucraina 32
CA - Canada 22
HK - Hong Kong 15
RU - Federazione Russa 15
EU - Europa 14
JP - Giappone 14
RO - Romania 13
CH - Svizzera 11
ES - Italia 10
IL - Israele 9
AU - Australia 7
BR - Brasile 6
GR - Grecia 5
TR - Turchia 5
BE - Belgio 4
CL - Cile 4
EG - Egitto 4
IR - Iran 4
MX - Messico 4
NZ - Nuova Zelanda 4
LT - Lituania 3
PK - Pakistan 3
SA - Arabia Saudita 3
SM - San Marino 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
BZ - Belize 2
CO - Colombia 2
CU - Cuba 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
KR - Corea 2
NO - Norvegia 2
PH - Filippine 2
AM - Armenia 1
BG - Bulgaria 1
GH - Ghana 1
HR - Croazia 1
ID - Indonesia 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MA - Marocco 1
MK - Macedonia 1
PL - Polonia 1
PT - Portogallo 1
QA - Qatar 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 32.304
Salva come PNG Salva come JPEG
Città #
Fairfield 5.630
Woodbridge 2.785
Ashburn 2.218
Houston 2.166
Seattle 2.010
Cambridge 1.856
Wilmington 1.599
Ann Arbor 1.328
Chandler 1.324
Singapore 940
Boardman 925
San Diego 720
Princeton 525
Medford 522
Santa Clara 421
Des Moines 392
Roxbury 367
Dong Ket 223
Helsinki 212
Padova 189
Beijing 163
Nanjing 135
Norwalk 88
Milan 76
London 67
Dublin 58
Rome 56
Shenyang 54
Hebei 37
Nanchang 33
Guangzhou 32
Jiaxing 31
Kilburn 30
Orange 30
Jinan 27
Jacksonville 26
New York 25
Kharkiv 23
Fort Worth 19
Pune 19
Los Angeles 18
Naples 18
Ogden 17
Tianjin 15
Verona 15
Vicenza 15
Frankfurt am Main 13
Borås 12
Hong Kong 12
Lappeenranta 12
Southwark 12
Springfield 12
Acton 11
Rockville 11
Rovigo 11
Changsha 10
Munich 10
Prineville 10
Taizhou 10
Dallas 9
Hounslow 9
Prescot 9
Chicago 8
Genoa 8
Legnaro 8
Modena 8
Palermo 8
Tokyo 8
Walnut 8
Bari 7
Chiswick 7
Florence 7
Fremont 7
Geneva 7
Redmond 7
San Donà di Piave 7
Venice 7
Haikou 6
Lanzhou 6
New Bedfont 6
Zhengzhou 6
Berlin 5
Chita 5
Falls Church 5
Fuzhou 5
Groningen 5
Malmo 5
Paris 5
Pisa 5
Venezia 5
Washington 5
Amsterdam 4
Bologna 4
Brendola 4
Buffalo 4
Cairo 4
Council Bluffs 4
Delhi 4
Forest City 4
Gavirate 4
Totale 27.874
Salva come PNG Salva come JPEG
Nome #
Regulation of Endoplasmic Reticulum-Mitochondria contacts by Parkin via Mfn2 185
Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation 164
USP14 inhibition corrects an in vivo model of impaired mitophagy 142
Brain structural profile of multiple system atrophy patients with cognitive impairment 114
The relationship between cerebral vascular disease and parkinsonism: The VADO study 113
A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation 113
Adherence to anti-Parkinson drug therapy in the "rEASON" sample of Italian patients with Parkinson's disease: The linguistic validation of the Italian version of the "morisky Medical Adherence scale-8 items" 111
Cognitive profiling of Parkinson disease patients with mild cognitive impairment and dementia 106
Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) performance in progressive supranuclear palsy and multiple system atrophy 106
Anatomical Correlates of Cognitive Functions in Early Parkinson's Disease Patients 105
[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors 104
Switching from constant voltage to constant current in deep brain stimulation: A multicenter experience of mixed implants for movement disorders 104
Globus pallidus internus deep brain stimulation for the treatment of status dystonicus in tardive dystonia 104
Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial 104
[11C]Raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length 103
Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease 102
Do patients with late-stage Parkinson's disease still respond to levodopa? 101
MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study 100
The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease 100
Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset 100
Diagnosing dementia in multiple system atrophy by applying Movement Disorder Society diagnostic criteria for Parkinson's disease dementia 99
Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review 98
Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group 98
Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform 97
Levodopa–carbidopa intrajejunal gel in advanced Parkinson disease with “on” freezing of gait 95
Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study 95
Effects of rotigotine on Parkinson's disease-related sleep disturbances 95
Spinal cord stimulation for the treatment of sensory symptoms in advanced Parkinson's disease 95
Deep brain stimulation for monogenic Parkinson’s disease: a systematic review 93
Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features. 92
Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts 91
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside 91
Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER 89
Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease 89
The neural correlates of spatial and object working memory in elderly and Parkinson's disease subjects 89
Psychosis associated to Parkinson's disease in the early stages: Relevance of cognitive decline and depression 89
PINK1 heterozygous rare variants: Prevalence, significance and phenotypic spectrum 89
Dynamic functional connectivity changes associated with dementia in Parkinson's disease 89
Foot pressure wearable sensors for freezing of gait detection in parkinson’s disease 89
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: An evidence-based review 88
Valvular heart disease and the use of dopamine agonists for Parkinson's disease 87
Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease 87
Anhedonia and cognitive impairment in Parkinson's disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study 87
Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial 87
Early DEtection of wEaring off in Parkinson disease: The DEEP study 87
Dopaminergic treatment and nonmotor features of Parkinson disease: The horse lives 87
Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson’s disease patients 87
Dysphagia predicts poor outcome in late-stage Parkinson's disease 87
ICARUS study: Prevalence and clinical features of impulse control disorders in Parkinson's disease 86
Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study 86
Reasons for hospitalization in Parkinson's disease: A case-control study 86
Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias 86
Nutritional habits, risk, and progression of Parkinson disease 86
Intrajejunale Levodopa- und Apomorphin-Infusion zur Therapie motorischer Komplikationen bei fortgeschrittener Parkinson-Krankheit 86
Relationship between pain and motor and non-motor symptoms in Parkinson's disease. 86
Grey matter changes in cognitively impaired Parkinson's disease patients 85
Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration 85
Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease 85
Motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study 85
Relevance of sleep quality on caregiver burden in Parkinson’s disease 85
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease 85
The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system 84
Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease 84
The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life 84
A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists 84
Targeting pain in Parkinson's disease 84
Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies 83
Therapy-resistant symptoms in Parkinson’s disease 83
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease 83
A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. 83
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire 83
[123I]FP-CIT SPET imaging in drug-induced Parkinsonism 83
Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach 83
Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease 83
Anatomical identification of active contacts in subthalamic deep brain stimulation 82
Validation of the Italian version of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale 82
Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study 82
Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report 82
Double-blind randomized trial of t-DCS versus sham in Parkinson patients with mild cognitive impairment receiving cognitive training 82
Peripheral neuropathy and levodopa therapy in Parkinson disease: Novel insights 81
Thin section MR study of the basal ganglia in the differential diagnosis between striatonigral degeneration and Parkinson disease 81
Adenosine A2A receptor antagonists in Parkinson's disease: Still in the running 81
Novel levodopa formulations in the treatment of Parkinson's disease 81
Beneficial Effects of Bilateral Subthalamic Stimulation on Non-Motor Symptoms in Parkinson's Disease 81
Rapid onset of efficacy of rasagiline in early Parkinson's disease 81
A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type 81
Anatomical profile of cognitive impairment in MSA 81
DBS for Parkinson's disease with behavioural disturbances 81
Disease progression in Parkinson subtypes: the PPMI dataset 81
Idiopathic delayed-onset edema surrounding deep brain stimulation leads: Insights from a case series and systematic literature review 81
Brain flow changes before and after deep brain stimulation of the subthalamic nucleus in Parkinson's disease 81
Predicting rapid progression of Parkinson's Disease at baseline patients evaluation 81
Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study 81
Dopamine transporter spect imaging in corticobasal syndrome 80
Managing for the long-term - Strategies for initiating and maintaining successful continuous dopaminergic stimulation treatment 80
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients 80
Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy 80
The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. 80
Relationship between pain and motor and non-motor symptoms in Parkinson's disease 80
Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease 80
Totale 9.127
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.871
article - articoli 137.065
book - libri 64
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 880
Totale 278.880
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.906 0 0 0 0 0 550 755 805 861 476 275 184
2020/20214.359 194 241 124 237 185 548 248 319 701 354 595 613
2021/20227.608 474 994 1.053 414 223 412 473 780 321 285 697 1.482
2022/20233.658 856 80 70 317 810 439 10 319 473 29 189 66
2023/20242.100 90 288 194 147 121 176 156 92 70 106 308 352
2024/20253.025 55 683 544 385 1.224 134 0 0 0 0 0 0
Totale 33.218